FDA Delays Off-Label Rule Opposed By Big Pharma

Law360, New York (March 17, 2017, 7:42 PM EDT) -- Bowing to pressure from Big Pharma, the U.S. Food and Drug Administration on Friday delayed by one year a controversial new rule that endorsed a broad approach to determining whether drug and device makers are engaged in off-label promotion.

The delay to March 19, 2018 came in response to a citizen petition filed last month by Pharmaceutical Research and Manufacturers of America, the Biotechnology Innovation Organization and a drugmaker coalition called the Medical Information Working Group. The petition, which sought a stay and reconsideration, strongly criticized...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.